UFPT

UFP TECHNOLOGIES INC

8 filings tracked

industrialspackaging solutionsMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 26

Planned retirement of General Counsel and SVP of Human Resources.

management change

60%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

bullishMay 8

Net income grew to $17.5 million with a slight increase in gross margin to 28.8%.

earnings beat

60%

bullishMay 8

Gross margin improved to 28.8% driven by efficiencies in robotic surgery.

margin expansion

40%

bearishMay 8

SG&A expenses increased 12.3% due to higher headcount and RSU compensation.

dilution risk

30%

neutralMay 8

Company utilizing a $275M credit facility with $137.6M in outstanding borrowings.

debt restructure

50%

Filing History

8-KMay 26, 2026

The filing of this 8-K marks a pivotal leadership transition for UFP Technologies as it navigates a phase of aggressive growth. While the company frames the departure of Christopher Litterio as a planned retirement, the breadth of his roles—spanning legal, secretarial, and human resources—creates a temporary void in senior oversight. The market's reaction will likely depend on the company's ability to quickly appoint a qualified successor and maintain stability in its compliance and people operations. Ultimately, the event highlights the tension between the need for fresh leadership to scale the business and the risk of losing seasoned institutional knowledge during a period of expansion.

10-QMay 8, 2026

The Q1 2026 filing reveals a company at a crossroads between secular medical growth and operational instability. On one hand, UFP's ability to capture demand in the robotic surgery space and its successful integration of new acquisitions demonstrate a clear path to scaling. The potential for tariff refunds and the resolution of labor issues provide concrete catalysts that could drive a valuation rerating in the coming quarters. However, the volatility in operating cash flow and the heavy concentration of revenue among a few key accounts introduce a layer of risk that cannot be ignored. Investors must weigh the high-quality growth of the medical segment against the reality of a tightening cash position and the pressure of quarterly debt obligations. The ultimate trajectory of the stock will likely depend on whether the promised recovery in wound care and the realization of tariff credits can offset the current working capital pressures.